Cargando…

Is the apparently protective effect of maternal nicotine replacement therapy (NRT) used in pregnancy on infant development explained by smoking cessation?: secondary analyses of a randomised controlled trial

OBJECTIVE: To investigate relationships between maternal smoking status in pregnancy and infant development. The largest randomised controlled trial of nicotine replacement therapy (NRT) for smoking cessation in pregnancy, the smoking, nicotine and pregnancy (SNAP) trial, found that at 1 month after...

Descripción completa

Detalles Bibliográficos
Autores principales: Iyen, Barbara, Vaz, Luis R, Taggar, Jaspal, Cooper, Sue, Lewis, Sarah, Coleman, Tim
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6629395/
https://www.ncbi.nlm.nih.gov/pubmed/31300493
http://dx.doi.org/10.1136/bmjopen-2018-024923
_version_ 1783435103432605696
author Iyen, Barbara
Vaz, Luis R
Taggar, Jaspal
Cooper, Sue
Lewis, Sarah
Coleman, Tim
author_facet Iyen, Barbara
Vaz, Luis R
Taggar, Jaspal
Cooper, Sue
Lewis, Sarah
Coleman, Tim
author_sort Iyen, Barbara
collection PubMed
description OBJECTIVE: To investigate relationships between maternal smoking status in pregnancy and infant development. The largest randomised controlled trial of nicotine replacement therapy (NRT) for smoking cessation in pregnancy, the smoking, nicotine and pregnancy (SNAP) trial, found that at 1 month after randomisation, smoking cessation rates were doubled in the NRT group compared with the placebo group. At delivery, there was no significant difference in cessation rates between groups. Surprisingly, infants born to women randomised to NRT were more likely to have unimpaired development at 2 years. We hypothesised that this apparently protective effect was due to smoking cessation caused by NRT and so, investigate this relationship using the same cohort. DESIGN: Secondary analysis of a randomised controlled trial. SETTING: Seven antenatal hospitals in the Midlands and North-West England. PARTICIPANTS: Eight hundred and eighty-four pregnant smokers randomised to receive either NRT patches or visually-identical placebo in the SNAP trial. Participants’ smoking behaviour were recorded at randomisation, 1 month after their target quit date and at delivery. METHODS: Using logistic regression models, we investigated associations between participants’ smoking measures and infant development (assessed using the Ages and Stages questionnaire) at 2 years. MAIN OUTCOME MEASURES: 2 year infant development. RESULTS: Developmental impairment was reported for 12.7% of study 2 year olds. Maternal heaviness of smoking at randomisation (OR: 1.26, 95% CI: 0.82 to 1.96, p=0.091), validated smoking abstinence recorded at 1 month after a quit date (OR: 1.02, 95% CI: 0.60 to 1.74, p=0.914) and validated smoking abstinence recorded at both 1 month after a quit date and at the end of pregnancy (OR: 1.52, 95% CI: 0.81 to 2.85, p=0.795) were not independently associated with infant developmental impairment at 2 years. CONCLUSION: We found no evidence that NRT treatment improved infants' developmental outcomes through smoking cessation. TRIAL REGISTRATION NUMBER: CTA03057/0002/001-0001; Post-results
format Online
Article
Text
id pubmed-6629395
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher BMJ Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-66293952019-07-30 Is the apparently protective effect of maternal nicotine replacement therapy (NRT) used in pregnancy on infant development explained by smoking cessation?: secondary analyses of a randomised controlled trial Iyen, Barbara Vaz, Luis R Taggar, Jaspal Cooper, Sue Lewis, Sarah Coleman, Tim BMJ Open Smoking and Tobacco OBJECTIVE: To investigate relationships between maternal smoking status in pregnancy and infant development. The largest randomised controlled trial of nicotine replacement therapy (NRT) for smoking cessation in pregnancy, the smoking, nicotine and pregnancy (SNAP) trial, found that at 1 month after randomisation, smoking cessation rates were doubled in the NRT group compared with the placebo group. At delivery, there was no significant difference in cessation rates between groups. Surprisingly, infants born to women randomised to NRT were more likely to have unimpaired development at 2 years. We hypothesised that this apparently protective effect was due to smoking cessation caused by NRT and so, investigate this relationship using the same cohort. DESIGN: Secondary analysis of a randomised controlled trial. SETTING: Seven antenatal hospitals in the Midlands and North-West England. PARTICIPANTS: Eight hundred and eighty-four pregnant smokers randomised to receive either NRT patches or visually-identical placebo in the SNAP trial. Participants’ smoking behaviour were recorded at randomisation, 1 month after their target quit date and at delivery. METHODS: Using logistic regression models, we investigated associations between participants’ smoking measures and infant development (assessed using the Ages and Stages questionnaire) at 2 years. MAIN OUTCOME MEASURES: 2 year infant development. RESULTS: Developmental impairment was reported for 12.7% of study 2 year olds. Maternal heaviness of smoking at randomisation (OR: 1.26, 95% CI: 0.82 to 1.96, p=0.091), validated smoking abstinence recorded at 1 month after a quit date (OR: 1.02, 95% CI: 0.60 to 1.74, p=0.914) and validated smoking abstinence recorded at both 1 month after a quit date and at the end of pregnancy (OR: 1.52, 95% CI: 0.81 to 2.85, p=0.795) were not independently associated with infant developmental impairment at 2 years. CONCLUSION: We found no evidence that NRT treatment improved infants' developmental outcomes through smoking cessation. TRIAL REGISTRATION NUMBER: CTA03057/0002/001-0001; Post-results BMJ Publishing Group 2019-07-11 /pmc/articles/PMC6629395/ /pubmed/31300493 http://dx.doi.org/10.1136/bmjopen-2018-024923 Text en © Author(s) (or their employer(s)) 2019. Re-use permitted under CC BY. Published by BMJ. This is an open access article distributed in accordance with the Creative Commons Attribution 4.0 Unported (CC BY 4.0) license, which permits others to copy, redistribute, remix, transform and build upon this work for any purpose, provided the original work is properly cited, a link to the licence is given, and indication of whether changes were made. See: https://creativecommons.org/licenses/by/4.0/.
spellingShingle Smoking and Tobacco
Iyen, Barbara
Vaz, Luis R
Taggar, Jaspal
Cooper, Sue
Lewis, Sarah
Coleman, Tim
Is the apparently protective effect of maternal nicotine replacement therapy (NRT) used in pregnancy on infant development explained by smoking cessation?: secondary analyses of a randomised controlled trial
title Is the apparently protective effect of maternal nicotine replacement therapy (NRT) used in pregnancy on infant development explained by smoking cessation?: secondary analyses of a randomised controlled trial
title_full Is the apparently protective effect of maternal nicotine replacement therapy (NRT) used in pregnancy on infant development explained by smoking cessation?: secondary analyses of a randomised controlled trial
title_fullStr Is the apparently protective effect of maternal nicotine replacement therapy (NRT) used in pregnancy on infant development explained by smoking cessation?: secondary analyses of a randomised controlled trial
title_full_unstemmed Is the apparently protective effect of maternal nicotine replacement therapy (NRT) used in pregnancy on infant development explained by smoking cessation?: secondary analyses of a randomised controlled trial
title_short Is the apparently protective effect of maternal nicotine replacement therapy (NRT) used in pregnancy on infant development explained by smoking cessation?: secondary analyses of a randomised controlled trial
title_sort is the apparently protective effect of maternal nicotine replacement therapy (nrt) used in pregnancy on infant development explained by smoking cessation?: secondary analyses of a randomised controlled trial
topic Smoking and Tobacco
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6629395/
https://www.ncbi.nlm.nih.gov/pubmed/31300493
http://dx.doi.org/10.1136/bmjopen-2018-024923
work_keys_str_mv AT iyenbarbara istheapparentlyprotectiveeffectofmaternalnicotinereplacementtherapynrtusedinpregnancyoninfantdevelopmentexplainedbysmokingcessationsecondaryanalysesofarandomisedcontrolledtrial
AT vazluisr istheapparentlyprotectiveeffectofmaternalnicotinereplacementtherapynrtusedinpregnancyoninfantdevelopmentexplainedbysmokingcessationsecondaryanalysesofarandomisedcontrolledtrial
AT taggarjaspal istheapparentlyprotectiveeffectofmaternalnicotinereplacementtherapynrtusedinpregnancyoninfantdevelopmentexplainedbysmokingcessationsecondaryanalysesofarandomisedcontrolledtrial
AT coopersue istheapparentlyprotectiveeffectofmaternalnicotinereplacementtherapynrtusedinpregnancyoninfantdevelopmentexplainedbysmokingcessationsecondaryanalysesofarandomisedcontrolledtrial
AT lewissarah istheapparentlyprotectiveeffectofmaternalnicotinereplacementtherapynrtusedinpregnancyoninfantdevelopmentexplainedbysmokingcessationsecondaryanalysesofarandomisedcontrolledtrial
AT colemantim istheapparentlyprotectiveeffectofmaternalnicotinereplacementtherapynrtusedinpregnancyoninfantdevelopmentexplainedbysmokingcessationsecondaryanalysesofarandomisedcontrolledtrial